Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Bridged-Ring Compounds
  • Genes, BRCA1
  • Genes, BRCA2
  • Germ-Line Mutation
  • Prostatic Neoplasms
  • Taxoids

abstract

  • • In this small, hypothesis-generating study approximately half of BRCA carriers had a prostate-specific antigen response to taxane-based chemotherapy, suggesting that it is an active therapy in these individuals.

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3971723

Digital Object Identifier (DOI)

  • 10.1111/j.1464-410X.2011.10292.x

PubMed ID

  • 21756279

Additional Document Info

start page

  • 713

end page

  • 9

volume

  • 109

number

  • 5